Aleksandra Filipovic MD, PhD, is head of oncology at PureTech, where she manages Oncology Asset Sourcing, review of oncology/ immuno oncology technologies and platforms from academia world-wide as well as biotech assets and pipelines amenable for commercialization and partnership. She is also responsible for pre-clinical and clinical development of therapeutics, prognostics/diagnostics and treatment delivery and imaging modalities from concept all the way leading up to product launch.
Previously, Dr. Filipovic served as associate medical director of Bristol Myers Squibb (New York) for early phase oncology and immuno-oncology clinical trials. She graduated from medical school at the Faculty of Medicine University of Nis, Serbia, and completed her PhD on the identification and validation of novel therapeutic targets in breast cancer and monoclonal antibody drug development at Imperial College in London, UK. Following this, she received a Fellowship from the College for the continuation of the translational research work and continued clinical practice in medical oncology.
Dr. Filipovic is also a practicing clinician at Imperial College NHS trust, faculty member at European School of Oncology, scientific committee member of Sharing Progress in Cancer Care (SPCC), associate editor for Frontiers in Oncology, and a member of American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC).